Wambulwa Charles, Bwayo Salome, Laiyemo Adeyinka O, Lombardo Fredric
Howard University College of Medicine, Washington, DC, USA.
J Natl Med Assoc. 2005 Dec;97(12):1725-8.
We present a 46-year-old African-American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of meningitis after using trimethoprim/sulfamethoxazole (TMP/SMX). TMP/SMX is primarily used for the treatment of pneumocystis carinii pneumonia prophylaxis in AIDS patients. Drug-induced aseptic meningitis (DIAM) is commonly seen with nonsteroidal anti-inflammatory drugs (NSAIDS), antibiotics (with TMP/SMX being the most frequently implicated), intravenous immunoglobulins and OKT3 antibodies. However, the implication of TMP/SMX inducing aseptic meningitis has been underreported to FDA/MEDWATCH program. This might be due to the fact that it has also been used to treat bacterial meningitis from organisms like Listeria monocytogenes, which is a common pathogen in the elderly and in infants. We reviewed the literature in an attempt to characterize the pattern and predictors of TMP/SMX-induced aseptic meningitis.
我们报告了一名46岁的非裔美国艾滋病男性患者,他在使用甲氧苄啶/磺胺甲恶唑(TMP/SMX)后三周内两次因脑膜炎的症状和体征入院。TMP/SMX主要用于预防艾滋病患者的卡氏肺孢子虫肺炎。药物性无菌性脑膜炎(DIAM)常见于非甾体抗炎药(NSAIDs)、抗生素(其中TMP/SMX最常涉及)、静脉注射免疫球蛋白和OKT3抗体。然而,TMP/SMX诱发无菌性脑膜炎的情况向美国食品药品监督管理局/医疗观察计划(FDA/MEDWATCH program)报告得较少。这可能是因为它也被用于治疗由单核细胞增生李斯特菌等病原体引起的细菌性脑膜炎,而单核细胞增生李斯特菌是老年人和婴儿中的常见病原体。我们查阅了文献,试图描述TMP/SMX诱发无菌性脑膜炎的模式和预测因素。